PLCG1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using PLCG1 mouse mAb against Hela (1), A431 (2), C6 (3), NIH/3T3 (4), COS7 (5), and HCT116 (6) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using PLCG1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using PLCG1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using PLCG1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using PLCG1 mouse mAb with DAB staining.    

  
  

PLCG1 (Phospholipase C Gamma 1) is a critical enzyme in intracellular signaling, primarily involved in hydrolyzing phosphatidylinositol 4.5-bisphosphate (PIP2) into secondary messengers inositol 1.4.5-trisphosphate (IP3) and diacylglycerol (DAG). These molecules regulate diverse cellular processes, including calcium mobilization, protein kinase C (PKC) activation, and cell proliferation. PLCG1 is activated by receptor tyrosine kinases (RTKs) and immune receptors (e.g., T-cell/B-cell receptors) through tyrosine phosphorylation, particularly at residues like Y783 and Y1254. enabling its role in growth factor signaling and immune cell activation.

PLCG1 antibodies are essential tools for studying its expression, activation, and interactions in pathways linked to cancer, inflammation, and immune disorders. They are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to detect PLCG1 levels, phosphorylation status, or subcellular localization. Dysregulation of PLCG1 is implicated in malignancies (e.g., breast cancer, glioblastoma) and autoimmune diseases, making these antibodies valuable for mechanistic and therapeutic research. Commercial PLCG1 antibodies are typically raised against specific epitopes, with validation emphasizing specificity for human, mouse, or rat isoforms. Researchers must select antibodies validated for particular applications or post-translational modifications to ensure accurate experimental outcomes.